.jpeg)
When will Sacituzumab govitecan be included in medical insurance?
In 2022, Sacituzumab govitecan was approved by the National Medical Products Administration to be marketed in China for the treatment of breast cancer in adults previously treated with endocrine therapy and at least two other cancer drugs; after treatment with platinum cancer drugs and immunotherapy, gosatuzumab is also used to treat bladder cancer and urinary tract cancer in adults. Since gosatuzumab, the original drug, has been on the domestic market for a short time and has not been included in the national medical insurance coverage, the specific time when it will enter the medical insurance ranks is not yet clear. Patients can consult the local medical insurance bureau or hospital. The price of domestic Specifications per bottle of 100 mg may be around 10,000 yuan, which is relatively expensive.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
